.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,013,002

« Back to Dashboard

Claims for Patent: 8,013,002

Title:Methods of administering pirfenidone therapy
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
Inventor(s): Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA)
Assignee: Intermune, Inc. (Brisbane, CA)
Application Number:13/049,894
Patent Claims: 1. A method of administering pirfenidone and fluvoxamine concurrently to a patient in need thereof comprising administering a therapeutically effective amount of fluvoxamine to the patient and administering a therapeutically effective amount of pirfenidone to the patient, wherein the amount of the pirfenidone is about 801 mg/day.

2. The method of claim 1 wherein the pirfenidone is administered three times per day.

3. The method of claim 2 wherein the patient has idiopathic pulmonary fibrosis (IPF).

4. The method of claim 3 wherein the pirfenidone is administered to the patient with food.

5. The method of claim 1 further comprising discontinuing co-administration of fluvoxamine and administering a therapeutically effective amount of pirfenidone.

6. A method of providing pirfenidone therapy to a patient in need thereof comprising titrating the dosage of pirfenidone administered to the patient downward from a dose of about 2400 mg/day, while co-administering fluvoxamine, wherein the dose of pirfenidone is reduced by about 1600 mg/day.

7. The method of claim 6 wherein about 800 mg/day of pirfenidone is administered to the patient.

8. The method of claim 6 wherein the pirfenidone is administered three times per day.

9. The method of claim 8 wherein the patient has idiopathic pulmonary fibrosis (IPF).

10. The method of claim 9 wherein the pirfenidone is administered to the patient with food.

11. The method of claim 6 further comprising discontinuing co-administration of fluvoxamine and administering about 2400 mg/day of pirfenidone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc